Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. IRTC
stocks logo

IRTC

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Financial AI Agent
Financial AI Agent

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
199.94M
+21.67%
0.059
+494.8%
191.26M
+20.54%
-0.548
-42.35%
217.20M
+16.34%
-0.074
-76.79%
Estimates Revision
The market is revising Upward the revenue expectations for iRhythm Technologies, Inc. (IRTC) for FY2025, with the revenue forecasts being adjusted by 1.67% over the past three months. During the same period, the stock price has changed by 0.17%.
Revenue Estimates for FY2025
Revise Upward
up Image
+1.67%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-18.69%
In Past 3 Month
Stock Price
Go Up
up Image
+0.17%
In Past 3 Month
Wall Street analysts forecast IRTC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IRTC is 219.62 USD with a low forecast of 185.00 USD and a high forecast of 244.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
14 Analyst Rating
Wall Street analysts forecast IRTC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IRTC is 219.62 USD with a low forecast of 185.00 USD and a high forecast of 244.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
12 Buy
2 Hold
0 Sell
Strong Buy
Current: 181.350
sliders
Low
185.00
Averages
219.62
High
244.00
Current: 181.350
sliders
Low
185.00
Averages
219.62
High
244.00
Morgan Stanley
Overweight
maintain
$195 -> $205
2025-12-02
New
Reason
Morgan Stanley
Price Target
$195 -> $205
2025-12-02
New
maintain
Overweight
Reason
Morgan Stanley raised the firm's price target on iRhythm to $205 from $195 and keeps an Overweight rating on the shares. Going into 2026, MedTech "looks well-positioned on several fronts" as the firm thinks major product cycles and a supportive hospital spending environment, combined with trough valuations, make for "a solid industry setup," the analyst tells investors in a note for the group on the upcoming year.
Goldman Sachs
David Roman
Neutral
maintain
$180 -> $202
2025-11-03
Reason
Goldman Sachs
David Roman
Price Target
$180 -> $202
2025-11-03
maintain
Neutral
Reason
Goldman Sachs analyst David Roman raised the firm's price target on iRhythm to $202 from $180 and keeps a Neutral rating on the shares.
Truist
Richard Newitter
Buy
maintain
$205 -> $230
2025-11-02
Reason
Truist
Richard Newitter
Price Target
$205 -> $230
2025-11-02
maintain
Buy
Reason
Truist analyst Richard Newitter raised the firm's price target on iRhythm to $230 from $205 and keeps a Buy rating on the shares. The company delivered a clean Q3 beat and raise result fueled by core business strength, Zio AT adoption, and progress with innovative channel partners, the analyst tells investors in a research note. The increase in FY25 revenue guidance signals the management's confidence in broad portfolio momentum going forward, the firm added.
Oppenheimer
Oppenheimer
Outperform
maintain
$175 -> $225
2025-10-31
Reason
Oppenheimer
Oppenheimer
Price Target
$175 -> $225
2025-10-31
maintain
Outperform
Reason
Oppenheimer raised the firm's price target on iRhythm to $225 from $175 and keeps an Outperform rating on the shares. The firm notes Q3 revenue came in at $193M, bucking the seasonal trend and ahead of its/consensus $184M/$185M estimates.
JPMorgan
Overweight
maintain
$190 -> $240
2025-10-31
Reason
JPMorgan
Price Target
$190 -> $240
2025-10-31
maintain
Overweight
Reason
JPMorgan raised the firm's price target on iRhythm to $240 from $190 and keeps an Overweight rating on the shares. The company reported "another broad-based beat" and is positioned for another year of upside in 2026, the analyst tells investors in a research note.
Goldman Sachs
David Roman
Neutral
maintain
$180 -> $202
2025-10-31
Reason
Goldman Sachs
David Roman
Price Target
$180 -> $202
2025-10-31
maintain
Neutral
Reason
Goldman Sachs analyst David Roman raised the firm's price target on iRhythm to $202 from $180 and keeps a Neutral rating on the shares. The firm updated its model following the Q3 earnings report.
See All Ratings

Valuation Metrics

The current forward P/E ratio for iRhythm Technologies Inc (IRTC.O) is -365.92, compared to its 5-year average forward P/E of -64.30. For a more detailed relative valuation and DCF analysis to assess iRhythm Technologies Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-64.30
Current PE
-365.92
Overvalued PE
5.81
Undervalued PE
-134.42

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
191.86
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
1092.81
Undervalued EV/EBITDA
-709.08

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
7.11
Current PS
0.00
Overvalued PS
10.40
Undervalued PS
3.83
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areSelling! The selling amount has increased 281.11% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

IRTC News & Events

Events Timeline

(ET)
2025-11-21
08:18:42
iRhythm unveils new findings on Zio's extended continuous ECG monitoring.
select
2025-11-17 (ET)
2025-11-17
10:00:06
iRhythm Experiences a 8.5% Decline
select
2025-11-11 (ET)
2025-11-11
08:09:52
iRhythm Reveals Study Publication in Heart Rhythm Journal
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
7.0
12-03Newsfilter
iRhythm Technologies Faces Shareholder Lawsuit Over Misrepresentation of Zio AT Monitor
  • Shareholder Lawsuit Investigation: Kuehn Law is investigating whether officers of iRhythm Technologies breached their fiduciary duties to shareholders, particularly regarding undisclosed information about the Zio AT monitor's intended use, potentially exposing shareholders to losses.
  • Market Misrepresentation: Executives repeatedly touted the growth potential of the Zio AT as an innovative product, failing to clarify that it was a real-time monitor for high-risk patients, leading investors to misinterpret its premium pricing.
  • Stock Price Impact: As a result of these misleading statements, iRhythm's stock traded at artificially inflated prices during relevant periods, which may result in financial losses for shareholders in the future.
  • Urgency of Legal Action: Kuehn Law urges shareholders to contact them promptly to enforce their rights within a limited timeframe, emphasizing that shareholder voices are crucial for maintaining the integrity and fairness of financial markets.
[object Object]
Preview
7.0
12-01PRnewswire
Halper Sadeh Investigates iRhythm Technologies for Potential Fiduciary Breaches
  • Shareholder Rights Investigation: Halper Sadeh LLC is investigating whether certain officers and directors of iRhythm Technologies, Inc. breached their fiduciary duties, potentially impacting the company's governance structure.
  • Legal Relief Options: Long-term shareholders of iRhythm stock may seek corporate governance reforms, return of funds, or court-approved financial incentive awards, aimed at enhancing company transparency and accountability.
  • Importance of Shareholder Participation: Shareholder involvement can improve the company's policies and oversight mechanisms, thereby enhancing shareholder value and demonstrating the company's commitment to shareholder interests.
  • Legal Fee Arrangement: Halper Sadeh LLC will handle the case on a contingency fee basis, meaning shareholders will not be responsible for legal fees, reducing the financial risk of participation.
[object Object]
Preview
9.0
11-21Newsfilter
New Findings from the Asia Pacific Heart Rhythm Society (APHRS) 2025 Showcase the Effectiveness of iRhythm's Zio Long-Term Continuous Monitoring in Asian Patients

  • New Data Presentation: iRhythm Technologies presented findings at the APHRS and JHRS 2025 sessions, demonstrating the effectiveness of their Zio long-term ECG monitoring system across diverse populations, including a large cohort of over 400,000 U.S. patients.

  • Comparable Performance: The analysis revealed that Asian patients showed similar device compliance and arrhythmia detection rates compared to non-Asian patients, indicating that racial and cultural factors did not significantly impact the performance of the Zio system.

  • Low Repeat Testing Rates: Both Asian and non-Asian groups exhibited low rates of repeat testing (approximately 15%), consistent with previous studies, reinforcing the reliability of the Zio long-term continuous monitoring approach.

  • Expansion in Japan: As Japan faces a growing need for advanced cardiac monitoring due to an aging population, iRhythm is collaborating with local investigators to validate the Zio system's performance and support its adoption in Japanese clinical practice.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is iRhythm Technologies Inc (IRTC) stock price today?

The current price of IRTC is 181.35 USD — it has decreased -0.92 % in the last trading day.

arrow icon

What is iRhythm Technologies Inc (IRTC)'s business?

iRhythm Technologies, Inc. is a digital health care company, which creates solutions that detect, predict, and prevent disease. The Company designs, develops, and commercializes device-based technology to provide ambulatory cardiac monitoring services. It offers three Zio System options: the Zio Monitor System, the Zio XT System, and the Zio AT System. It offers its Zio ambulatory cardiac monitoring services, including long-term continuous monitoring, short-term continuous monitoring, and mobile cardiac telemetry (MCT) monitoring services (Zio Services), using its Zio Systems. The Zio Monitor System is a prescription-only, remote ECG monitoring system that consists of a patch ECG monitor (the Zio Monitor patch) that records the electric signal from the heart continuously for up to 14 days and the Zio ECG Utilization Software (ZEUS) System, which supports the capture and analysis of ECG data recorded by the Zio Monitor patch at the end of the wear period.

arrow icon

What is the price predicton of IRTC Stock?

Wall Street analysts forecast IRTC stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IRTC is 219.62 USD with a low forecast of 185.00 USD and a high forecast of 244.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is iRhythm Technologies Inc (IRTC)'s revenue for the last quarter?

iRhythm Technologies Inc revenue for the last quarter amounts to 192.88M USD, increased 30.74 % YoY.

arrow icon

What is iRhythm Technologies Inc (IRTC)'s earnings per share (EPS) for the last quarter?

iRhythm Technologies Inc. EPS for the last quarter amounts to -0.16 USD, decreased -89.19 % YoY.

arrow icon

What changes have occurred in the market's expectations for iRhythm Technologies Inc (IRTC)'s fundamentals?

The market is revising Upward the revenue expectations for iRhythm Technologies, Inc. (IRTC) for FY2025, with the revenue forecasts being adjusted by 1.67% over the past three months. During the same period, the stock price has changed by 0.17%.
arrow icon

How many employees does iRhythm Technologies Inc (IRTC). have?

iRhythm Technologies Inc (IRTC) has 2000 emplpoyees as of December 05 2025.

arrow icon

What is iRhythm Technologies Inc (IRTC) market cap?

Today IRTC has the market capitalization of 5.84B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free